ArticleMolecular cancer research : MCR2018
ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.
Article in Molecular cancer research : MCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 104 citations in OpenAlex.
- NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.Cancer discovery · 2024Trial
- Article
- Cancer-associated fusion transcripts: mechanisms, functional roles, and clinical implications.Clinical and experimental medicine · 2026Review
- Importance of Multimodal Testing for Novel ALK Fusions: A Case of MTHFD1L-ALK Positive Lung Squamous Cell Carcinoma With Negative IHC.Thoracic cancer · 2026Article
- ALK Inhibitor Response in NovelJTO clinical and research reports · 2026Article
- EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis.Cancer discovery · 2026Article
- Durable response to ALK inhibition in low-allele-frequencyFrontiers in oncology · 2026Article
- Analysis of clinical features and outcomes in a Chinese cohort withFrontiers in oncology · 2026Article
- Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and RNA-based gene fusion analysis.The oncologist · 2025Article
- Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib.Science signaling · 2025Article
- Refining Criteria for Choosing the First-Line Treatment for Real-World Patients with AdvancedInternational journal of molecular sciences · 2025Review
- ALK in cancer: from function to therapeutic targeting.Nature reviews. Cancer · 2025Review
- Inflammatory Myofibroblastic Tumor: An Updated Review.Cancers · 2025Review
- Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function.Scientific reports · 2025Article
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review.The oncologist · 2025Review
- Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer.International journal of general medicine · 2025Review
- Case Report: Clinical response of ensartinib for inflammatory myofibroblastic tumor of the urinary bladder with multiple metastases and TPM4-ALK fusion.Frontiers in oncology · 2025Article
- A rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring aTranslational lung cancer research · 2024Article
- Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada.Current oncology (Toronto, Ont.) · 2024Article
- Alectinib treatment for 2 non-small cell lung carcinoma patients carrying different novelZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Oncogenic tyrosine kinase fusions involving the anaplastic lymphoma kinase (ALK) are detected in numerous tumor types. Although more than 30 distinct 5' fusion partner genes have been reported, treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.